Salix Pharmaceuticals, Ltd. (SLXP) and Pharming Group NV (PHARM) Monday announced that the Food and Drug Administration has extended the Prescription Drug User Fee Act, or PDUFA, action date to July 16, 2014 for Biologics License Application for the investigational drug Ruconest, or recombinant human C1 esterase inhibitor, 50 IU/kg.
The companies are seeking U.S. marketing approval of Ruconest for treatment of acute angioedema attacks in patients with hereditary angioedema. Salix Pharma is a pharmaceutical products and medical devices company. Pharming Group develops innovative products for treatment of unmet medical needs.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.